Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
341 studies found for:    NR3C2
Show Display Options
Rank Status Study
1 Completed Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size
Condition: ST-elevation Myocardial Infarction
Interventions: Drug: Mineralocorticoid receptor antagonist potassium-canrenoate;   Drug: placebo
2 Recruiting Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease
Conditions: Chronic Kidney Disease;   Albuminuria
Interventions: Drug: Spironolactone;   Drug: Amiloride
3 Enrolling by invitation Mineralocorticoid Receptor Antagonist and Kidney Allograft Histology
Condition: Kidney Failure, Chronic
Intervention: Drug: spironolactone
4 Recruiting Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance
Condition: Heart Failure
Interventions: Drug: Spironolactone 100mg;   Drug: Spironolactone 25mg
5 Recruiting Mineralocorticoid Receptor Antagonists in Type 2 Diabetes
Condition: Diabetes Type 2
Interventions: Drug: Eplerenone;   Drug: Placebo
6 Recruiting Hypoglycemia and the Mineralocorticoid Receptor
Condition: Hypoglycemia
Intervention: Drug: Eplerenone
7 Completed Mineralocorticoid Receptor in the Treatment of Severe Depression
Condition: Major Depression
Interventions: Drug: Spironolactone;   Drug: fludrocortisone;   Drug: escitalopram
8 Recruiting Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure
Condition: Heart Failure
Intervention: Drug: Spironolacton
9 Completed Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease
Conditions: Type 2 Diabetes Mellitus;   Vascular Disease
Interventions: Drug: Spironolactone;   Drug: hydrochlorothiazide + potassium;   Other: placebo
10 Completed Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications
Conditions: Obesity;   Insulin Resistance
Interventions: Drug: Spironolactone;   Drug: Placebo
11 Completed Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure. AREA IN-CHF Study
Condition: Heart Failure
Intervention: Drug: Canrenone
12 Recruiting Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial
Condition: Atherosclerosis
Interventions: Drug: Eplerenone;   Drug: Placebo
13 Completed
Has Results
The Role of Mineralocorticoid Receptors in Vascular Function
Condition: Apparent Mineralocorticoid Excess (AME)
Interventions: Drug: Glycyrrhetic Acid;   Drug: Placebo
14 Unknown  Mineralocorticoid Receptor Antagonists in End Stage Renal Disease
Condition: End Stage Renal Disease / Hemodialysis
Interventions: Drug: Spironolactone;   Drug: Placebo
15 Unknown  Aldosterone and the Metabolic Syndrome
Conditions: Metabolic Diseases;   Diabetes Mellitus;   Endocrine System Diseases;   Glucose Metabolism Disorders
Interventions: Drug: Renin-Angiotensin-Aldosterone System (RAAS) Activation;   Drug: Administration of Aliskiren, Spironolactone, or Placebo;   Drug: Increased Dose, Combination, or Placebo
16 Completed Eplerenone and Extracellular Adenosine Formation
Condition: Pharmacodynamics
Interventions: Drug: Eplerenone;   Drug: Placebo
17 Completed Cardiovascular Evaluation of Adult PHA 1 Patients
Condition: Pseudohypoaldosteronism Type 1
Intervention:
18 Completed Search of Biomarkers of Mineralocorticoid Receiver Activity : the Value of Neutrophil Gelatinase Associated Lipocalin (NGAL)in Serum or Urine in Human
Condition: Cardiovascular Diseases
Interventions: Procedure: Urinary and blood lipococalin levels determination;   Drug: Spironolactone
19 Recruiting Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas
Condition: Primary Aldosteronism
Interventions: Other: Adrenalectomy;   Drug: mineralocorticoid receptor antagonist
20 Not yet recruiting Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)
Condition: HIV
Interventions: Drug: Eplerenone;   Drug: Placebo;   Behavioral: Lifestyle Modification

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.